Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.4%

Twist Bioscience Co. (NASDAQ:TWST)’s share price fell 4.4% during mid-day trading on Tuesday . The stock traded as low as $27.90 and last traded at $27.95. 98,884 shares were traded during mid-day trading, a decline of 89% from the average session volume of 907,806 shares. The stock had previously closed at $29.24.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent analyst reports. Scotiabank upped their price target on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. Barclays dropped their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th.

Twist Bioscience Trading Down 2.5 %

The stock has a market capitalization of $1.65 billion, a P/E ratio of -8.10 and a beta of 1.62. The business has a 50-day moving average price of $36.15 and a 200 day moving average price of $29.89.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. The firm had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company’s quarterly revenue was up 31.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.74) EPS. On average, sell-side analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now owns 516,409 shares in the company, valued at $19,329,188.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the transaction, the chief executive officer now owns 516,409 shares in the company, valued at $19,329,188.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,132 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the transaction, the chief executive officer now owns 514,149 shares in the company, valued at approximately $16,833,238.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,037 shares of company stock worth $384,092. 3.92% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock valued at $8,965,000 after purchasing an additional 14,511 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in Twist Bioscience by 559.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock valued at $2,159,000 after purchasing an additional 90,413 shares in the last quarter. Dark Forest Capital Management LP boosted its position in Twist Bioscience by 121.3% during the third quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock valued at $597,000 after purchasing an additional 16,142 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Twist Bioscience during the third quarter valued at about $451,000. Finally, Citigroup Inc. boosted its position in Twist Bioscience by 94.1% during the third quarter. Citigroup Inc. now owns 264,204 shares of the company’s stock valued at $5,353,000 after purchasing an additional 128,098 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.